BOSTON, April 24, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that
Partnerships in Clinical Trials named PAREXEL's Drew Garty, Senior Director, Product Management,
the 2015 Clinical Innovator of the Year. The honor recognizes
Mr. Garty's leadership of the product development team for the
Company's Perceptive MyTrials® Data-Driven Monitoring
solution.
After accepting the award Thursday night during the 2015
Partnership Awards in Boston, Mr.
Garty stated, "The development of our Perceptive MyTrials
Data-Driven Monitoring (DDM) solution was a significant team effort
with a clear goal of meeting a customer need. I am honored to
accept this award from Partnerships in Clinical Trials on behalf of
the team in recognition of PAREXEL's innovative approach to
risk-based monitoring."
On-site monitoring is a critical aspect of trial management,
with the primary function of identifying and mitigating patient
safety or data quality risks at investigative sites. The U.S.
Food and Drug Administration (FDA) and other regulatory bodies have
issued guidance to assist sponsors in developing risk-based
monitoring strategies. The goal of these strategies is to enhance
patient protection and improve trial data quality through more
effective study oversight.
The Perceptive MyTrials Data-Driven Monitoring solution uses a
unique algorithmic-based approach to clinical monitoring to
determine risk and monitor workload, enabling flexible and scalable
decision making. DDM allows drug developers to accurately identify
study risks and efficiently determine the most effective monitoring
interventions required. As a result, drug developers can enhance
quality and patient safety, reduce costs and ensure regulatory
compliance.
"Through the Perceptive MyTrials Data-Driven Monitoring
solution, we have greater insights into study data. These
insights can make clinical trial participation safer for patients,
improve decision making during the drug development journey and
offer cost efficiencies for sponsors," said Xavier Flinois,
President of PAREXEL Informatics. "Our data-driven monitoring
solution builds on PAREXEL's established history of developing
innovative technologies to continuously improve clinical processes,
and we are thrilled to be recognized by Partnerships in Clinical
Trials."
About Partnership in Clinical Trials and the Partnership
Awards
The Partnerships in Clinical Trials event is
North America's largest conference
serving the global clinical trials, operations and outsourcing
community. The Partnership Awards honor the accomplishments of
clinical trial leaders who have influenced change within the
industry through innovation. The Clinical Innovator of the
Year Award honors a person or company with a disruptive technology
platform or a new way to optimize clinical development that has
increased the efficiency of clinical trials.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 81
locations in 51 countries around the world, and has approximately
16,530 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, and Perceptive MyTrials are
trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates. All other trademarks are the
property of their respective owners.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of Quantum Solutions India and ClinIntel
Limited, or enter into new lines of business; the impact on the
Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter
ended December 31, 2014 as filed with the Securities and
Exchange Commission on February 5, 2015, which "Risk Factors"
discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL
International
Tel: +1 781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Jenny Gardynski, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-honored-with-2015-clinical-innovator-of-the-year-award-from-partnerships-in-clinical-trials-300067907.html
SOURCE PAREXEL International Corporation